At a glance
ClinicalIndex Comparison RecordN/AUnknown· 29 enrolled
Drug / intervention
Aflibercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
In Brief
An observational study evaluating Aflibercept and Indocyanine green angiography (intraveonus indocyanine green dye) for Polypoidal Choroidal Vasculopathy. Targeting 29 participants across 1 site.
Detailed Summary
To compare the short-term effect of intravitreal aflibercept injection between two subtypes of polypoidal choroidal vasculopathy
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPolypoidal Choroidal Vasculopathy
CountriesSouth Korea
Collaborators--
Timeline
N/AUnknownOverdue
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedNov 2015
Primary CompletionDec 2015
Study CompletionAug 2016
TodayJul 2026
First PostedNov 5, 2015
Enrollment StartSep 1, 2015
Primary CompletionDec 1, 2015
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.7 years ago
Interventions
Afliberceptdrug
Total 4 times of intravitreal aflibercept injection was performed
Indocyanine green angiography (intraveonus indocyanine green dye)drug
At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.